Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis C

A compound having the formula:

• or a pharmaceutically acceptable salt thereof, wherein:
• A is a 9- to 10-membered bicyclic heteroaryl containing one N atom and optionally, one to two additional heteroatoms independently selected from the group consisting of N, O, and S, wherein A is substituted on one ring carbon atom with R3, and wherein A is optionally substituted on one to two ring carbon atoms with R3a and is optionally substituted on one ring nitrogen atom with R1;
• B is a ring selected from the group consisting of:
• wherein B is optionally substituted on one or more ring carbon atoms by one to three R10;
• and wherein when B is
• then A and D are each bonded to a common ring of B;
• D is a 9 to 10-membered bicyclic heteroaryl containing one N atom and optionally, one to two additional heteroatoms independently selected from the group consisting of N, O, and S, wherein D is substituted on one ring carbon atom with R4, and wherein D is optionally substituted on one two carbon atoms with R4a and is optionally substituted on one ring nitrogen atom with R2;
• R3 and R4 are independently selected from the group consisting of:
• wherein R3 and R4 are optionally and independently substituted with:
• (a) one to two fluorine or C1-C3 alkyl;
• (b) and one to seven 2H;
• each occurrence of R3a and R4a is independently selected from the group consisting of H, C1-C3 alkyl, C1-C3 alkoxy, halo, and C1-C3 trifluoroalkoxy;
• R1 and R2 are independently H or C1-C3 alkyl;
• each occurrence of R5 is independently selected from the group consisting of:
• (a) —C(O)—(C1-C6 alkyl) optionally substituted by one to eight R12 groups, wherein R12 is selected from the group consisting of:
• (i) C1-C3 alkoxy,
• (ii) phenyl, optionally substituted by one to four halo, C1-C3 alkyl, or C1-C3 alkoxy;
• (iii) amino,
• (iv) C1-C3 monoalkylamino,
• (v) C1-C3 dialkylamino,
• (vi) —NHC(O)—O—(C1-C6 alkyl),
• (vii) —N(C1-C3 alkyl)—C(O)—O—(C1-C6 alkyl),
• (viii) C1-C3 fluoroalkyl,
• (ix) C2-C6 alkynyl,
• (x) C3-C7 cycloalkyl,
• (xi) pyrrolidinyl,
• (xii) piperidinyl,
• (xiii) pyranyl;
• and
• (xiv) 2H;
• (b)
• wherein x is 1 or 2, and each occurrence of R6 is independently selected from the group consisting of H, C1-C3 alkyl, C1-C3 alkoxy, and fluoro;
• and
• (c) H;
• each occurrence of R10 is independently 2H, halo, C1-C6 alkyl, C2-C6 alkenyl, C2-C6alkynyl, C1-C6 alkoxy, cyano, and phenyl;
• and
• R10a is H or C1-C6 alkyl.